Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has Concert Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CNCE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CNCE's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: CNCE underperformed the US Biotechs industry which returned 31.4% over the past year.
Return vs Market: CNCE underperformed the US Market which returned 44.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Concert Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StWe're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
3 months ago | Simply Wall StConcert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years
5 months ago | Simply Wall StHow Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?
Is Concert Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CNCE's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CNCE's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CNCE is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CNCE is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CNCE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CNCE is good value based on its PB Ratio (1.2x) compared to the US Biotechs industry average (3.5x).
How is Concert Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CNCE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CNCE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CNCE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CNCE's revenue (63% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: CNCE's revenue (63% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CNCE's Return on Equity is forecast to be high in 3 years time
How has Concert Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CNCE is currently unprofitable.
Growing Profit Margin: CNCE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CNCE is unprofitable, and losses have increased over the past 5 years at a rate of 28.9% per year.
Accelerating Growth: Unable to compare CNCE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CNCE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: CNCE has a negative Return on Equity (-67.48%), as it is currently unprofitable.
How is Concert Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: CNCE's short term assets ($123.9M) exceed its short term liabilities ($8.3M).
Long Term Liabilities: CNCE's short term assets ($123.9M) exceed its long term liabilities ($17.6M).
Debt to Equity History and Analysis
Debt Level: CNCE is debt free.
Reducing Debt: CNCE had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CNCE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CNCE has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 24% each year.
What is Concert Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CNCE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CNCE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CNCE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CNCE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CNCE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Roger Tung (60 yo)
Dr. Roger D. Tung, Ph.D., Co-founded Concert Pharmaceuticals, Inc. in April 2006 and has been its Chief Executive Officer and President since April 2006. Dr. Tung worked in venture-backed start-up and majo...
CEO Compensation Analysis
Compensation vs Market: Roger's total compensation ($USD3.02M) is above average for companies of similar size in the US market ($USD526.91K).
Compensation vs Earnings: Roger's compensation has increased whilst the company is unprofitable.
Experienced Management: CNCE's management team is seasoned and experienced (5.2 years average tenure).
Experienced Board: CNCE's board of directors are seasoned and experienced ( 14 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.5%.
Concert Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Concert Pharmaceuticals, Inc.
- Ticker: CNCE
- Exchange: NasdaqGM
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$139.312m
- Shares outstanding: 32.17m
- Website: https://www.concertpharma.com
Number of Employees
- Concert Pharmaceuticals, Inc.
- 65 Hayden Avenue
- Suite 3000N
- United States
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. Its lead product candidate is CTP-543...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/12 23:20|
|End of Day Share Price||2021/06/11 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.